Log in
NASDAQ:IMRN

Immuron Stock Forecast, Price & News

$7.55
-0.08 (-1.05 %)
(As of 11/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$7.35
Now: $7.55
$7.72
50-Day Range
$6.01
MA: $7.25
$8.50
52-Week Range
$1.55
Now: $7.55
$28.99
Volume51,893 shs
Average Volume1.06 million shs
Market Capitalization$42.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.
Read More
Immuron logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMRN
CUSIPN/A
CIKN/A
Phone(138) 892-4854
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.69 million
Book Value$0.69 per share

Profitability

Miscellaneous

Market Cap$42.30 million
Next Earnings DateN/A
OptionableNot Optionable
$7.55
-0.08 (-1.05 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immuron (NASDAQ:IMRN) Frequently Asked Questions

How has Immuron's stock been impacted by COVID-19?

Immuron's stock was trading at $2.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IMRN stock has increased by 190.4% and is now trading at $7.55.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Immuron?

Wall Street analysts have given Immuron a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immuron wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Immuron?

Immuron saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 13,300 shares, an increase of 56.5% from the October 15th total of 8,500 shares. Based on an average trading volume of 97,800 shares, the short-interest ratio is currently 0.1 days.
View Immuron's Short Interest
.

Who are some of Immuron's key competitors?

What other stocks do shareholders of Immuron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immuron investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), CRISPR Therapeutics (CRSP), Dynavax Technologies (DVAX), OPKO Health (OPK), AbbVie (ABBV) and Co-Diagnostics (CODX).

Who are Immuron's key executives?

Immuron's management team includes the following people:
  • Jerry Kanellos, Chief Executive & Operating Officer
  • Phillip Allen Hains, Chief Financial Officer & Secretary
  • Reza Moussakhani, Director-Manufacturing Quality
  • Travis Robins, Director-US Sales

When did Immuron IPO?

(IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.

What is Immuron's stock symbol?

Immuron trades on the NASDAQ under the ticker symbol "IMRN."

Who are Immuron's major shareholders?

Immuron's stock is owned by many different institutional and retail investors. Top institutional shareholders include Courage Capital Management LLC (2.06%) and Morgan Stanley (0.24%).

Which institutional investors are selling Immuron stock?

IMRN stock was sold by a variety of institutional investors in the last quarter, including Courage Capital Management LLC.

Which institutional investors are buying Immuron stock?

IMRN stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley.

How do I buy shares of Immuron?

Shares of IMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immuron's stock price today?

One share of IMRN stock can currently be purchased for approximately $7.55.

How big of a company is Immuron?

Immuron has a market capitalization of $42.30 million and generates $1.69 million in revenue each year.

What is Immuron's official website?

The official website for Immuron is www.immuron.com.au.

How can I contact Immuron?

Immuron's mailing address is 62 LYGON STREET LEVEL 3, CARLTON C3, 3053. The company can be reached via phone at (138) 892-4854 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.